Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics (BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BOLD
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $15.47
  • 50 Day Moving Average: $15.73
  • 200 Day Moving Average: $16.54
  • 52-Week Range: $13.06 - $20.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.32
  • P/E Growth: -0.57
  • Market Cap: $338.84M
  • Outstanding Shares: 21,889,000
Profitability:
  • Return on Assets: -41.00%
Debt:
  • Debt-to-Equity Ratio: -0.03%
  • Current Ratio: 12.35%
  • Quick Ratio: 12.35%

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (42.12% upside)

Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
9/1/2016WedbushReiterated RatingOutperform$20.00N/AView Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 4/28/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Earnings History by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017        
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
Current Year EPS Consensus Estimate: $-3.87 EPS
Next Year EPS Consensus Estimate: $-3.58 EPS

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership Percentage: 70.99%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Audentes Therapeutics (NASDAQ:BOLD)
Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
Source:
DateHeadline
americanbankingnews.com logoInsider Buying: Audentes Therapeutics Inc (BOLD) Insider Buys 172,413 Shares of Stock
www.americanbankingnews.com - April 26 at 10:52 PM
americanbankingnews.com logo-$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - April 25 at 5:18 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 24 at 4:42 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Prices 5.2M Share Offering at $14.50/Sh
www.streetinsider.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - April 19 at 1:12 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:57 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 17 at 12:26 PM
americanbankingnews.com logoZacks Investment Research Downgrades Audentes Therapeutics Inc (BOLD) to Sell
www.americanbankingnews.com - April 11 at 4:34 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:37 PM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
us.rd.yahoo.com - April 3 at 4:24 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 24 at 7:22 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "" by Analysts
www.americanbankingnews.com - March 24 at 12:23 PM
finance.yahoo.com logoAudentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
finance.yahoo.com - March 20 at 11:52 AM
finance.yahoo.com logoAUDENTES THERAPEUTICS, INC. Financials
finance.yahoo.com - March 16 at 3:40 PM
americanbankingnews.com logoFY2021 Earnings Estimate for Audentes Therapeutics Inc (BOLD) Issued By Wedbush
www.americanbankingnews.com - March 13 at 2:48 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 11:49 AM
finance.yahoo.com logoAudentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 4:34 PM
finance.yahoo.com logoAudentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
finance.yahoo.com - March 1 at 9:16 AM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
us.rd.yahoo.com - February 1 at 4:13 PM
us.rd.yahoo.com logo8:01 am Audentes Therapeutics announces that the FDA has cleared the investigational new drug (IND) application for AT342
us.rd.yahoo.com - February 1 at 4:13 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives FDA Clearance of IND Application for AT342 to Treat Crigler-Najjar Syndrome
www.streetinsider.com - February 1 at 4:13 PM
finance.yahoo.com logoAudentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logo8:04 am Audentes Therapeutics's cash position is projected to fund operations into late 2018; provides FY17 milestones
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 4:57 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 13 at 4:40 PM
finance.yahoo.com logoAudentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
finance.yahoo.com - November 30 at 5:43 AM
finance.yahoo.com logoAudentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference
finance.yahoo.com - November 21 at 8:49 AM
bizjournals.com logoSupersized IPO charges up med device maker's first day
www.bizjournals.com - October 21 at 12:12 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - September 28 at 8:59 AM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - September 2 at 8:38 AM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - September 1 at 12:23 PM
bizjournals.com logoBay Area cosmetics company files for $100M IPO
www.bizjournals.com - August 31 at 3:52 PM
wsj.com logo[$$] Biotech Investor Sofinnova Ventures Raises $595.5M Toward New Fund
www.wsj.com - August 25 at 8:47 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Enrolls First Patient in INCEPTUS Study of XLMTM
www.streetinsider.com - August 18 at 12:20 PM
finance.yahoo.com logoAudentes Therapeutics Initiated Overweight At Wedbush
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoAudentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoCoverage initiated on Audentes Therapeutics by Wedbush
finance.yahoo.com - August 15 at 11:07 AM
finance.yahoo.com logoAudentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 8:43 AM
247wallst.com logo4 IPOs on Calendar for Week of July 25
247wallst.com - July 24 at 10:55 AM

Social

Frequently Asked Questions for Audentes Therapeutics (NASDAQ:BOLD)

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) issued its quarterly earnings results on Thursday, March, 9th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.16.

When will Audentes Therapeutics make its next earnings announcement?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?

3 analysts have issued 1 year price objectives for Audentes Therapeutics' shares. Their predictions range from $20.00 to $24.00. On average, they anticipate Audentes Therapeutics' stock price to reach $22.00 in the next year.

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Audentes Therapeutics stock?

Audentes Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FLYNN JAMES E (7.59%), Versant Venture Management LLC (8.25%), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.62%) and ProShare Advisors LLC (0.06%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc.

Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?

Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including ProShare Advisors LLC.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Audentes Therapeutics stock cost?

One share of Audentes Therapeutics stock can currently be purchased for approximately $15.48.

Audentes Therapeutics (BOLD) Chart for Friday, April, 28, 2017

This page was last updated on 4/28/2017 by MarketBeat.com Staff